In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

This week’s update looks at P-BCMA-ALLO1, a Cas-CLOVER-edited allogeneic CAR-T candidate that is being developed for the treatment of multiple...

Poseida Therapeutics' unique approach to gene editing and delivery addresses some of the major obstacles faced within cell and gene therapy...

Demeetra AgBio, headquartered in Kentucky, is pioneering a unique genome-editing technology called Cas-CLOVER. Applications include plant-based drug...